Kirsten impresses with the scope and scale of her global commercialization experiences at top-flight pharmaceutical corporations including Amgen, Bristol-Myers Squibb, and Takeda. During her career, she has launched or led several, multi-billion-dollar blockbusters, including Enbrel®, Entyvio®, Plavix®, and Prolia®. Her therapeutic expertise is in the field of immune-mediated inflammatory diseases (rheumatoid arthritis, Crohn’s Disease, ulcerative colitis and psoriasis), built during a career spanning more than 25 years in the pharmaceutical and biotech spaces.
Kirsten was previously Vice-President/Commercial Leader for Takeda’s Global GI franchise, where she launched Entyvio® (today, a $4 billion therapeutic). She was also General Manager of the company’s businesses in Austria, Czech Republic and Slovakia. Her access and reimbursement work is extensive and varied, having successfully negotiated insurance coverage for a variety of specialty care therapeutics in both US and international environments.
Kirsten has an M.B.A. from The Tuck School of Business at Dartmouth College and a B.A. in Chemistry from Middlebury College.